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A B S T R A C T
Hyponatremia is a common clinical condition among hospitalized heart failure pa-
tients, associated with increased morbidity and mortality. The pathophysiological 
mechanisms that relate heart failure with hyponatremia are complex, involving be-
yond renal dysfunction, neurohormonal activation and diuretic treatment. The pitui-
tary hormone vasopressin seems to play a central role leading to renal water reten-
tion and hyponatremia. Although therapeutic strategies (water restriction, hormone 
inhibition) have been shown to increase serum sodium concentration and improve 
symptoms, no beneficial effect has been detected on clinical outcome. This fact urges 
the need for the conduction of further clinical trials, in order to determine the causal-
ity between short- and long-term outcome and serum sodium concentration in heart 
failure patients.
I N T R O D U C T I O N
Hyponatremia represents one of the most common clinical metabolic disorders 
in patients with chronic heart failure. Hyponatremia, which is generally defined as 
Na concentrations below 135 meq/l, occurs in 10-20% of heart failure (HF) patients.1 
Several studies have revealed the prognostic role of serum Na concentrations on the 
clinical course of HF.2-5 The Acute Decompensated Heart Failure registry (ADHERE), 
which included 158,168 HF patients, showed a prevalence of 5% among patients on 
admission with serum sodium levels <130 meq/L. Those low Na concentrations were 
associated with increased mortality and morbidity.6 In the Organized Program to Initiate 
Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) 
registry, including 48,162 HF patients, 19.7% of the patients had hyponatremia on 
admission, which was also associated with prolonged hospitalization and higher in-
hospital mortality.7 Recently, from the Duke Databank for Cardiovascular Diseases, 
10% of the 1,045 patients, who were indentified with HF and systolic dysfunction, had 
hyponatremia. Those hyponatremic patients were older, more likely to have anemia, 
higher heart rate and levels of blood urea nitrogen, lower blood pressure, and more 
severe HF; while the multiadjusted analysis revealed that low serum Na was associated 
with poor cardiovascular outcome.8 Although the incidence of hyponatremia in hospi-
talized patients is well described, in stable outpatients the available data are limited. In 
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the Danish Heart Failure Clinics Network, which included 2883 
patients, the prevalence of hyponatremia was 17%, which was 
lower than in most previous studies of hospitalized patients.5 
Another study in a smaller outpatient population reported a 
hyponatremia (Na+<135 mEq/L) prevalence of 13%, and in 
the Spanish MUSIC-study the prevalence of hyponatremia 
(where it was unusually defined as Na<138 mmol/L) was found 
to be 38% (Table 1).9,10
PA T H O P H Y S I O L O G I C A L  M E C H A N I S M S
The renin-angiotensin-aldosterone (RAAS) system plays 
a crucial role in the progression of heart failure. The RAAS is 
TABLE 1. Studies of Association of Hyponatremia with Heart Failure Outcomes 
Study
No of 
patients Type of patients Outcome [Na] cut-off HR (95%CI)
DDCD8 1,045 Hospitalized patients 
with chronic systolic HF 
(NYHA II-IV)
4.5-year all-cause 
mortality, 
4.5-year CV mortality  
and rehospitalization
[Na] <135 mmol/L 1.45 (1.09-1.93)
1.45 (1.13-1.86)
HFSS8 268 Outpatients with systolic 
HF (NYHA III-IV)
1-year mortality [Na] per 1-mmol/L 
change (value after 
medical therapy 
optimization)
1.05 (1.00-1.08)
EFFECT2 2624 Hospitalized patients with 
systolic and diastolic HF 
(NYHA II-III)
30-day and 1-year 
mortality
[Na] <136 mmol/L 1.53 (1.14-2.05), for 30-day
mortality; 1.46 (1.19-1.80), 
for 1-year mortality
UK-HEART23 553 Outpatients with systolic 
HF (NYHA II-III)
5-year mortality [Na] per 2-mmol/L 
change [Na] <140 
mmol/L (baseline 
value)
1.13 (1.05-1.19)
Seattle Heart 
Failure Model4
1125 Hospitalized patients with 
systolic HF (NYHA II-IV)
1-, 2-, and 3-year  
mortality
[Na] <138 mol/L 1.05 (1.005-1.097)
MUSIC10 992 Outpatients with systolic 
and diastolic HF (NYHA 
II-III)
4-year mortality for total, 
cardiac, and pump failure 
mortality
[Na] <138mmol/L 1.35 (1.03-1.77), for 
cardiac
mortality;
1.60 (1.12-2.29), for pump 
failure mortality
ESCAPE24 433 Hospitalized patients 
with systolic HF (NYHA 
III-IV)
6-month mortality [Na] per 1-mmol/L 
change, [Na]<130 
mmol/L 
0.93 (0.87-0.99)
OPTIME-CHF25 949 Hospitalized patients 
with systolic HF (NYHA 
III-IV)
60-day mortality [Na] per 5-mmol/L 
change 
0.75 (0.60-0.95)
Danish Heart 
Failure Clinics 
Network5
3465 Outpatients with systolic 
HF
4.5years mortality [Na]<136 mmol/L HR 1.5 (1.2–1.9)
CI = confidence intervals; CV = cardiovascular; DDCD = Duke Databank for Cardiovascular Diseases; EFFECT = Enhanced Feedback for 
Effective Cardiac Treatment; ESCAPE = Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization 
Effectiveness; HF = heart failure; HFSS = Heart Failure Survival Score; HR = hazard ratio; MUSIC = Multi-Sensor Monitoring in Congestive 
Heart Failure; NYHA = New York Heart Association (classification); OPTIMISE-CHF = Outcomes of a Prospective Trial of 
Intravenous Milrinone for Exacerbations of Chronic Heart Failure; UK-HEART = United Kingdom Heart Failure Evaluation and 
Assessment of Risk Trial. 
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stimulated by a decrease in renal blood flow and by low blood 
salt concentration. RAAS is also stimulated by the increase 
in sympathetic tone that results from the decrease in arterial 
baroceptor stretch in heart failure. The excess of angiotensin II 
in heart failure causes systemic and arteriolar vasoconstriction, 
increase in aldosterone concentration, and increased thirst, 
which further exacerbates hyponatremia. The angiotensin and 
sympathetic pathways increase systemic vascular resistance and 
increase preload and arterial filling. The stimulation of vaso-
pressin release activates the movement of aquaporin-2 water 
channels to the apical membrane of the collecting duct where 
passive water reabsorption occurs. Additionally, aldosterone 
causes water and sodium reabsorption at the level of the col-
lecting duct. Furthermore, in patients with heart failure, there 
is a decrease in transport of sodium and water to the collecting 
duct, due to arterial underfilling and low circulating blood 
volume, which impairs the kidney’s ability to excrete dilute 
urine.11 It is important to emphasize that excess water intake, 
due to social interaction, especially in younger heart failure 
patients, can be another important reason for the occurrence of 
water imbalance and hyponatremia. Furthermore, excess water 
intake is noted in chronic psychiatric patients when treated 
with certain antipsychotic medications, which are often used 
in heart failure patients with depression and increase thirst 
through anticholinergic side effects.
Inappropriate arginine vasopressin (AVP) release is 
another explanation of hyponatremia. This situation repre-
sents excess release of AVP, despite low serum osmolality. 
Myocardial remodeling in response to excessive water reab-
sorption which expands ventricular preload and alterations 
in gap junction function can contribute to lower osmolality 
in patients with even normal renal function. In this condi-
tion, although the serum sodium remains low, the total body 
sodium is elevated and there is increased extracellular fluid 
volume. Low circulating blood volume has been proposed as 
the unifying etiology for this contradiction in volume states. In 
heart failure, the decrease in effective arterial filling leads to a 
decrease in baroreceptor stretch, a mechanism that mediates 
vasopressin release.12 Vasopressin release is mediated by both 
osmotic as well as cardiac output and intravascular volume 
stimuli. Those stimuli, mediated through high (aortic arch 
and carotid sinus) and low (left atrial) pressure baroreceptors 
enhance the secretion of AVP for any given osmotic stimulus. 
This hormone is synthesized in the supraoptic and paraven-
tricular nuclei of the hypothalamus and is released from the 
posterior pituitary. Its effects are multiple and related to the 
affected receptor. Vasopressin binding to the V1a receptor (in 
the vascular smooth muscle cells, myometrium and platelets) 
leads to vascular smooth muscle contraction; while V2 receptor 
activation in the renal medulla leads to free water reabsorption 
by the collecting duct. Binding of vasopressin to V2 receptors, 
located on the basolateral membrane of the cortical collecting 
duct cells, leads to increased aquaporin 2 mRNA levels and 
translocation of aquaporin-2 to the apical plasma membrane, 
which increases tubular water permeability and allows water to 
move from the tubule to the medullary interstitium, resulting 
in net reabsorption of free water.13,14 The lack of suppression 
of AVP release despite hypo-osmolality plays a pivotal role 
in the development of hyponatremia in patients with heart 
failure. This is due to the fact that water balance regulation is 
primarily designed to control serum osmolality and to a lesser 
extent blood volume. For that reason AVP starts to rise after 
a 1% increment in serum osmolality, compared to a 5–10% 
decrease in blood volume. Eventually, the need to return the 
perfusion pressure to normal limits leads to an inability of 
AVP suppression, at the cost of hyponatremia. Interestingly, 
Waikar et al illustrated that in patients with end-stage renal 
disease, the neurohormonal activation of advanced heart fail-
ure does not lead to water retention and hyponatremia through 
a vasopressin-mediated mechanism. Thus, any effect must be 
mediated by neurohormonal effects on thirst.15
Diuretic use is another cause of hyponatremia in HF 
patients. Loop diuretics are the most commonly utilized 
diuretics and exert their salt wasting effects by inhibiting the 
Na-K-Cl cotransporter (NKCC) channel in the thick ascending 
loop of Henle. Other diuretics used frequently in HF include 
thiazide diuretics and spironolactone. Thiazides inhibit the 
Na-Cl cotransporter in the distal convoluted tubule, while 
spironolactone prevents activation of the mineralocorticoid 
receptor on the principal cells of the cortical collecting duct. 
Of these 3 classes, loop diuretics offer the most potent increase 
in Na and water excretion and thus are important agents in 
the treatment of states of volume overload.16 Amiodarone can 
also cause hyponatremia, most probably due to a syndrome 
of inappropriate antidiuretic hormone hypersecretion 
(SIADH)-induced mechanism. Although this phenomenon 
occurs only rarely, it should be recognized by clinicians as a 
possible serious adverse effect of this drug. The mechanism 
of SIADH-induced hyponatremia secondary to amiodarone 
is unclear. One possible mechanism includes alterations on 
channel-modulating properties on renal or neural tissues.17
H Y P O N A T R E M I A :  M A R K E R  O R  M E D I A T O R ?
All these complex pathogenetic mechanisms of hypona-
tremia in HF patients lead to the crucial dilemma if hypona-
tremia reflects a mediator and not an independent marker 
of survival.18 Along with this thought comes the fact that in 
patients with HF hyponatremia is associated with higher levels 
of plasma renin, angiotensin II, aldosterone, epinephrine, 
norepinephrine, dopamine, and cortisol, and a greater degree 
of impairment of renal and hepatic blood flow. In patients 
hospitalized for heart failure, hyponatremia also is associated 
with lower systolic blood pressure, higher brain natriuretic pep-
tide, and higher likelihood of using inotropic agents. In these 
conditions, hyponatremia is mediated by nonosmotic release of 
AVP and reduced free water clearance by the kidney, which in 
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turn may reflect the severity of the underlying disease process 
through mechanisms such as reduced glomerular filtration rate 
and activation of the sympathetic nervous system. Additionally, 
in many studies, those patients with hyponatremia had higher 
prevalence of diabetes mellitus and were under higher-dose 
requirements of loop diuretics than normonatremic patients.19 
It is possible that hyponatremia might simply be a marker for 
high vasopressin levels, which, through the stimulation of V1a 
receptors, could alter outcome in chronic HF.20 Therefore, it 
is difficult to prove a causal association between hyponatre-
mia and poor clinical outcomes in congestive heart failure 
patients, due to the high likelihood of confounding by disease 
underlying severity.
M A N A G E M E N T  O F  H Y P O N A T R E M I A 
Hyponatremia can be classified according to the measured 
plasma osmolality as isotonic, hypertonic or hypotonic. Hypo-
natremia with a normal plasma osmolality usually indicates 
pseudohyponatremia, while hyponatremia because of a high 
plasma osmolality is typically caused by hyperglycemia. The 
syndrome of inappropriate ADH (SIADH) secretion should 
be suspected in any patient with euvolemic hyponatremia 
with a urine osmolality above 100 mOsm/kg and urine sodium 
concentration above 40 mEq/l. Management of hyponatremia 
includes optimization of medical therapy (RAAS antagonists, 
ą-blockers), preservation of renal function in normal limits 
and maintenance of appropriate fluid intake. In addition, the 
relatively newly developed vasopressin antagonists potentially 
offer an attractive therapeutic strategy for dealing with hypo-
natremia in HF.21 Feldman et al19 have recently demonstrated 
a role for V1a-mediated signaling in the development of HF, 
which supports a role for V1a blockade in the treatment of 
patients with elevated levels of vasopressin; although it has 
not yet been established whether the normalization of hy-
ponatremia (by fluid restriction or specific drugs) leads to a 
better prognosis.
The Acute and Chronic Therapeutic Impact of a Vaso-
pressin Antagonist in Congestive Heart Failure (ACTIV in 
CHF) trial using tolvaptan and the Efficacy of Vasopressin 
Antagonism in Heart Failure Outcome Study with Tolvaptan 
(EVEREST) trial, as well as the DILIPO-study where the 
short and long-term treatment of dilutional hyponatremia 
with satavaptan, a selective AVP V2-receptor antagonist, was 
examined, revealed positive results of AVP antagonist efficacy 
in increasing serum sodium concentrations. However, improve-
ment of clinical symptoms or survival was not reported in any of 
those studies.21,22 EVEREST was a prospective, international, 
multicenter, randomized, double-blind, placebo-controlled 
study, which enrolled 4133 heart failure patients (2072 received 
tolvaptan and 2061 received placebo). The first primary end 
point (all cause mortality) was not different; 25.9% vs 26.3% 
in the tolvaptan vs placebo groups (hazard ratio 0.98; 95% 
confidence intervals-CI 0.87–1.11; P = 0.68). The second 
primary end point (death from cardiovascular causes or first 
hospitalization for HF) was reached in 42% of the patients on 
tolvaptan compared with 40.2% in the placebo group (hazard 
ratio 1.04; 95% CI 0.95–1.14; P = 0.55). Improvement in the 
patient-assessed dyspnea score at day 1 was seen in 74.3% of 
tolvaptan patients with dyspnea at baseline compared with 
68.0% in the placebo group (P<0.001). Additionally, improve-
ment was noted in edema, total body weight and renal function 
in the tolvaptan group compared to placebo.22 Those results, 
despite the neutral effect of tolvaptan on cardiovascular and 
total outcome among patients with systolic HF, provide a basis 
for its use to correct moderate to severe hyponatremia among 
outpatients with systolic HF, in order to achieve rapid clinical 
improvement and reduce length of hospitalization. 
C O N C L U S I O N 
Hyponatremia represents a serious clinical condition in 
patients with advanced heart failure, which is associated with 
adverse outcome (Table 1).2,5,8,10,23-25 As the pathophysiologi-
cal mechanisms are complex, treatment strategies that have 
been used are limited and associated with adverse effects. 
Among them, dietary fluid restriction, diuretic therapy, and 
neurohormonal blockade are the traditional recommenda-
tions, but their efficacy is poorly documented. Even the use 
of vasopressin antagonists has shown neutral results on clini-
cal outcome. It seems rational that future studies addressing 
the effect of vasopressin antagonists or other therapeutic 
approaches on outcome in HF patients are needed, in order 
to determine the causality between hyponatremia and heart 
failure physical history.
R E F E R E N C E S
1. Farmakis D, Filippatos G, Parissis J, Kremastinos DT, Gheo-
rghiade M. Hyponatremia in heart failure. Heart Fail Rev 
2009;14:59-63.
2. Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV. 
Predicting mortality among patients hospitalized for heart 
failure derivation and validation of a clinical model. JAMA 
2003;290:2581-2587.
3. Kearney MT, Nolan J, Lee AJ, et al. A prognostic index to 
predict long-term mortality in patients with mild to moderate 
chronic heart failure stabilised on angiotensin converting en-
zyme inhibitors. Eur J Heart Fail 2003;5:489-497.
4. Levy WC, Mozaffarian D, Linker DT, et al. The Seattle Heart 
Failure Model: prediction of survival in heart failure. Circula-
tion 2006;113:1424-1433.
5. Balling L, Schou M, Videbæk L, Hildebrandt P, Wiggers H, 
Gustafsson F, for the Danish Heart Failure Clinics Network 
Prevalence and prognostic significance of hyponatraemia in 
outpatients with chronic heart failure. Eur J Heart Fail 2011;13: 
968–973.
HYPONATREMIA IN HEART FAILURE
95
6. Fonarow GC, Heywood JT, Heidenreich PA, Lopatin M, Yancy 
CW, ADHERE Scientific Advisory Committee and Investiga-
tors. Temporal trends in clinical characteristics, treatments, and 
outcomes for heart failure hospitalizations, 2002 to 2004: find-
ings from Acute Decompensated Heart Failure National Regis-
try (ADHERE). Am Heart J 2007;153:1021-1028.
7. Gheorghiade M, Abraham WT, Albert NM, et al, OPTIMIZE-
HF Investigators and Coordinators. Relationship between 
admission serum sodium concentration and clinical outcomes 
in patients hospitalized for heart failure: an analysis from the 
OPTIMIZE-HF registry. Eur Heart J 2007;28:980-988.
8. Bettari L, Fiuzat M, Shaw LD, et al. Hyponatremia and long-
term outcomes in chronic heart failure. An observational study 
from the Duke databank for cardiovascular diseases. J Cardiac 
Fail 2012;18:74-81. 
9. Dewolfe A, Lopez B, Arcement LM, Hebert K. Low serum so-
dium as a poor prognostic indicator for mortality in congestive 
heart failure patients. Clin Cardiol 2010;33:E13–17.
10. Vazquez R, Bayes-Genis A, Cygankiewicz I, et al, MUSIC In-
vestigators. The MUSIC Risk score: a simple method for pre-
dicting mortality in ambulatory patients with chronic heart fail-
ure. Eur Heart J 2009;30:1088–1096.
11. Sica DA. Sodium and water retention in heart failure and di-
uretic therapy: basic mechanisms. Cleve Clin J Med 2006;73(sup-
pl 2):S2-7.
12. Schrier RW. Water and sodium retention in edematous disor-
ders: role of vasopressin and aldosterone. Am J Med 2006;119 
(suppl 1):S47-53.
13. Nielsen S, Kwon TH, Christensen BM, Promeneur D, Frøkiær 
J, Marples D. Physiology and pathophysiology of renal aquapo-
rins. J Am Soc Nephrol 1999;10:647–663.
14. Farmakis D, Filippatos G, Kremastinos DT, Gheorghiade M. 
Vasopressin and vasopressin antagonists in heart failure and 
hyponatremia. Curr Heart Fail 2008;5:91-96.
15. Waikar SS, Curhan GC, Brunelli SM. Mortality associated with 
low serum sodium concentration in maintenance hemodialysis. 
Am J Med 2011; 124: 77–84.
16. Sica DA, Gehr TWB. Diuretic combinations in refractory oe-
dema states: pharmacokinetic- pharmacodynamic relationships. 
Clin Pharmacokin 1996;30:229–249.
17. Shavit E, Sherer Y. Hyponatremia induced by amiodarone ther-
apy. Isr Med Assoc J 2007;9:564-565.
18. Ghali JK, Tam SW. The critical link of hypervolemia and hy-
ponatremia in heart failure and the potential role of arginine 
vasopressin antagonists. J Card Fail 2010;16:419-431.
19. Li X, Chan TO, Myers V, et al. Controlled and cardiac-restrict-
ed overexpression of the arginine vasopressin V1A receptor 
causes reversible left ventricular dysfunction through GĄq-
mediated cell signaling. Circulation 2011;124:572-581.
20. Liamis G, Milionis H, Elisaf M. A review of drug induced 
hyponatremia. Am J Kidney Dis 2008; 52:144-153.
21. Aronson D, Verbalis JG, Mueller M, Krum H. Short- and long-
term treatment of dilutional hyponatraemia with satavaptan, a 
selective arginine vasopressin V2-receptor antagonist: the DIL-
IPO study. Eur J Heart Fail 2011;13:326–336.
22. Konstam MA, Gheorghiade M, Burnett JC, et al. Efficacy of 
Vasopressin Antagonism in Heart Failure Outcome Study With 
Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan 
in patients hospitalized for worsening heart failure: the EVER-
EST Outcome Trial. JAMA 2007;297:1319–1331.
23. Kearney MT, Fox KA, Lee AJ, et al. Predicting death due to 
progressive heart failure in patients with mild-to-moderate 
chronic heart failure. J Am Coll Cardiol 2002;40:1801–1808.
24. Gheorghiade M, Rossi JS, Cotts W, et al. Characterization and 
prognostic value of persistent hyponatremia in patients with 
severe heart failure in the ESCAPE Trial. Arch Intern Med 
2007;167:1998-2005.
25. Klein L, O’Connor CM, Leimberger JD, for the O-CHFI. 
Lower serum sodium is associated with increased short-term 
mortality in hospitalized patients with worsening heart failure: 
results from the outcomes of a prospective trial of intravenous 
milrinone for exacerbations of chronic heart failure (OPTIME-
CHF) study. Circulation 2005; 111:2454-2460.
